Pirtobrutinib vs ibrutinib in treatment-naïve and relapsed/refractory CLL/SLL: Results from the first randomized phase III study comparing a non-covalent and covalent BTK inhibitor
Randomized trial shows non-inferiority of overall response rate in treatment-naïve CLL, indicating potential advantages for pirtobrutinib over ibrutinib.
Key Points
Ibrutinib treatment produced an overall response rate of 78.6% vs 87.0% for pirtobrutinib in chronic lymphocytic leukemia.
In the ITT cohort, median age was 67, with pirtobrutinib showing a statistically significant improvement over ibrutinib in both TN and R/R populations.
Randomized phase III study comparing treatment-naïve patients receiving either pirtobrutinib or ibrutinib until progression or adverse events occurred.
Findings highlight a need for careful monitoring of adverse events, with distinct differences observed between treatment arms.